MONMOUTH JUNCTION, NJ--(Marketwire - October 25, 2007) - MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE.F), a medical device company focused on the development of its platform technology for removal of toxins from blood and physiologic fluids, announced today that it has acquired ownership of two patents from Robert Albright, Ph.D., a scientific consultant to the Company. The patents broaden the core technology related to CytoSorb™ polymer hemocompatibility and methods of manufacture.
